SSRI treatment decreases prolactin and hyperthermic responses to mCPP

We studied the effect of 3 weeks treatment with the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the neuroendocrine and hyperthermic responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP) (0.05 mg/kg i.v.), in seven healthy volunteers. Following par...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 1997-10, Vol.133 (3), p.305-308
Main Authors: QUESTED, D. J, SARGENT, P. A, COWEN, P. J
Format: Article
Language:English
Subjects:
Adult
Area Under Curve
Biological and medical sciences
Body Temperature - drug effects
Chlorophenylpiperazine
Cross-Over Studies
Female
Fever - chemically induced
Humans
Male
Medical sciences
Middle Aged
Neuropharmacology
Paroxetine
Paroxetine - pharmacology
Pharmacology. Drug treatments
Piperazines - pharmacology
Prolactin
Prolactin - blood
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Receptor mechanisms
Serotonin Receptor Agonists - pharmacology
Serotonin S2 receptors
Serotonin uptake inhibitors
Serotonin Uptake Inhibitors - pharmacology
Single-Blind Method
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We studied the effect of 3 weeks treatment with the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the neuroendocrine and hyperthermic responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP) (0.05 mg/kg i.v.), in seven healthy volunteers. Following paroxetine treatment, both the prolactin and hyperthermic responses to mCPP were significantly attenuated. These data are consistent with experimental animal studies indicating that repeated SSRI treatment leads to a functional desensitisation of 5-HT2C receptors. This effect may be linked to the anxiolytic properties of SSRIs.
ISSN:0033-3158
1432-2072
DOI:10.1007/s002130050406